tetano
Editor, Senior Moderator
Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618-0. doi: 10.1016/j.antiviral.2017.02.016. [Epub ahead of print]
[h=1]Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.[/h] Pendzialek J[SUP]1[/SUP], Roose K[SUP]2[/SUP], Smet A[SUP]2[/SUP], Schepens B[SUP]2[/SUP], Kufer P[SUP]1[/SUP], Raum T[SUP]1[/SUP], Baeuerle PA[SUP]1[/SUP], Muenz M[SUP]1[/SUP], Saelens X[SUP]2[/SUP], Fiers W[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The ectodomain of the influenza A matrix protein 2 (M2e) is highly conserved amongst all influenza virus A subtypes. M2e is present on the surface of influenza A virus-infected cells, and therefore a suitable target for broadly protective therapies. We designed bispecific T cell engaging (BiTE[SUP]?[/SUP]) antibody constructs specific for M2e by genetically fusing a single chain variable fragment (scFv) derived from an M2e-specific murine monoclonal antibody with a CD3ɛ-specific scFv. These so-called FLU BiTE[SUP]?[/SUP] antibody constructs selectively mediate T cell dependent lysis of M2-expressing and influenza A virus infected cells and protect BALB/c mice against challenge with different influenza A virus subtypes. By humanizing the M2e-binding scFv, we generated human-like FLU BiTE[SUP]?[/SUP] antibody constructs, with increased in vitro cytotoxic activity and in vivo protective capacity against influenza A virus infection. FLU BiTE[SUP]?[/SUP] antibody constructs represent a promising new curative and prophylactic treatment option for influenza disease.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Antiviral; Bispecific T cell engaging antibody constructs; Influenza virus; M2 ectodomain
PMID: 28257797 DOI: 10.1016/j.antiviral.2017.02.016
[PubMed - as supplied by publisher]
[h=1]Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.[/h] Pendzialek J[SUP]1[/SUP], Roose K[SUP]2[/SUP], Smet A[SUP]2[/SUP], Schepens B[SUP]2[/SUP], Kufer P[SUP]1[/SUP], Raum T[SUP]1[/SUP], Baeuerle PA[SUP]1[/SUP], Muenz M[SUP]1[/SUP], Saelens X[SUP]2[/SUP], Fiers W[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The ectodomain of the influenza A matrix protein 2 (M2e) is highly conserved amongst all influenza virus A subtypes. M2e is present on the surface of influenza A virus-infected cells, and therefore a suitable target for broadly protective therapies. We designed bispecific T cell engaging (BiTE[SUP]?[/SUP]) antibody constructs specific for M2e by genetically fusing a single chain variable fragment (scFv) derived from an M2e-specific murine monoclonal antibody with a CD3ɛ-specific scFv. These so-called FLU BiTE[SUP]?[/SUP] antibody constructs selectively mediate T cell dependent lysis of M2-expressing and influenza A virus infected cells and protect BALB/c mice against challenge with different influenza A virus subtypes. By humanizing the M2e-binding scFv, we generated human-like FLU BiTE[SUP]?[/SUP] antibody constructs, with increased in vitro cytotoxic activity and in vivo protective capacity against influenza A virus infection. FLU BiTE[SUP]?[/SUP] antibody constructs represent a promising new curative and prophylactic treatment option for influenza disease.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Antiviral; Bispecific T cell engaging antibody constructs; Influenza virus; M2 ectodomain
PMID: 28257797 DOI: 10.1016/j.antiviral.2017.02.016
[PubMed - as supplied by publisher]